Latest Nuvilex Inc (NVLX) Headlines Nuvilex A
Post# of 1086
Posted On: 03/10/2014 8:35:42 PM
Latest Nuvilex Inc (NVLX) Headlines
Nuvilex Appoints Dr. Garret L. Yount to Its Subsidiary's Scientific Advisory Board
GlobeNewswire - Fri Mar 07, 9:23AM CST
Nuvilex, Inc. (OTCQB:NVLX), an international biotechnology company providing cell and gene therapy solutions for the treatment of deadly diseases, announced today that its subsidiary, Medical Marijuana Sciences, Inc., has appointed Garret L. Yount, Ph.D. to its Scientific Advisory Board.
Nuvilex Partner Austrianova Establishes Regional Headquarters and Research and Development Facility at Thailand Science Park for Cell-in-a-Box(TM) Live-Cell Encapsulation
GlobeNewswire - Fri Mar 07, 2:59AM CST
Nuvilex, Inc. (OTCQB:NVLX), an international biotechnology company providing cell and gene therapy solutions for the treatment of diseases, announced today that its strategic partner, Austrianova, has signed a contract to establish regional Headquarters and a research and development facility at the Thailand Science Park (TSP) near Bangkok, Thailand. These facilities will be used for the encapsulation, using the Cell-in-a-Box technology, of live cancer prodrug-activating cells that are part of Nuvilex's pancreatic cancer treatment and that will be used in the Company's late-phase clinical trials involving this deadly disease.
Recent Events Effectively De-Risk Nuvilex, Inc.
PR Newswire - Thu Mar 06, 7:00AM CST
Goldman Small Cap Research, a stock market research firm focused on the small cap and micro cap sectors, recently published a new research update on Nuvilex Inc. (OTCQB: NVLX). In the update, senior analyst Rob Goldman outlines his latest thesis.
DirectView Enters Agreement with Colorado Marijuana Facility Developer; CannaBusiness Acquires NorCal Connection LLC
ACCESSWIRE - Wed Feb 26, 11:09AM CST
West Palm Beach, FL / February 26, 2014 / The Cannabis-Marijuana Sector is rapidly expanding as industry up and coming companies position themselves in this exploding sector. Four companies issuing news today are DirectView Holdings, Inc. (OTC: DIRV), The CannaBusiness Group, Inc (OTC: CBGI), Nuvilex, Inc. (OTC: NVLX) and PetroTech Oil and Gas, Inc. (OTC: PTOG). To be one of the first to get news as it occurs, visit http://www.marketnewsupdates.com/.
Nuvilex Comprehensive Analyst Report Answers Vital Questions for Shareholders, by BrokerBank Securities, Inc.
PR Newswire - Wed Feb 26, 6:00AM CST
Nuvilex, Inc. (OTCQB: NVLX) owns exclusive rights to a cancer treatment platform that has successfully completed Phase 2 clinical trials for inoperable pancreatic cancer. Nuvilex also owns rights to the same platform to treat diabetes, and the company also has a medical marijuana subsidiary slated to begin cancer research and development using cannabidiol. With each of the key target markets representing multi-billion-dollar opportunities, Nuvilex offers investors multiple opportunities for success and should trade at a valuation that reflects its current development progress to date.
10-K: OGE ENERGY CORP.
Edgar Online - Tue Feb 25, 7:22AM CST
Item 7. Management's Discussion and Analysis of Financial Condition and Results of Operations.
Chicago Investment Firm Assumes $27 Million Risk to Help Nuvilex Unseat Celgene and Eli Lilly
Marketwire - Mon Feb 24, 8:04AM CST
Lincoln Park Capital (LPC) purchased 8 million restricted shares of Nuvilex, Inc. (OTCQB: NVLX) in exchange for an initial $2 million out of what can be viewed as a $27 million "pot of money" to advance the company's late-phase pancreatic cancer clinical trials. Notice we said restricted shares, that's right, LPC has put a great deal of its money on the line with a number of built in protections for Nuvilex. But, is this investment really a risk? It appears the Chicago-based firm knows exactly what the future could hold for Nuvilex, and they're comfortable with paying a premium price to become a long-term investor right along with many others who believe in the small biotechnology firm.
Move Over Celgene Here Comes Nuvilex and $27 Million to Advance Its Pancreatic Cancer Clinical Trials
Marketwire - Fri Feb 21, 8:00AM CST
Nuvilex, Inc. (OTCQB: NVLX) just became relevant in the biotech industry. The company can now move forward with its clinical trials for the treatment of advanced inoperable pancreatic cancer after Nuvilex landed a $27 million funding deal that could change the sector for years to come. Funding is always the biggest hurdle for any small biotechnology or pharmaceutical firm, and its why larger firms with competing treatments can often sit back without worry of new competition.
Nuvilex Announces $27 Million Funding Commitment With Institutional Investor to Advance Late Phase Clinical Trials
GlobeNewswire - Thu Feb 20, 8:00AM CST
Nuvilex, Inc. (OTCQB:NVLX), an international biotechnology company providing cell and gene therapy solutions for the treatment of deadly diseases, announced today that it has entered into a stock purchase agreement with Lincoln Park Capital Fund, LLC (Lincoln Park), a Chicago-based institutional investor. Lincoln Park initially purchased 8 million shares of Nuvilex's common stock at $0.25 per share for $2 million and has committed to invest, at the sole option of Nuvilex, up to an additional $25 million of equity capital over the term of the purchase agreement. The proceeds from this investment will be used for Nuvilex's late-stage clinical trials in advanced inoperable pancreatic cancer, for research into the use of constituents of marijuana in the emerging medical marijuana arena and for general operating purposes.
Company To Provide Video Surveillance & Security Platform for Marijuana Facilities in Rapidly Evolving Cannabis Industry
PR Newswire - Thu Feb 20, 7:45AM CST
Medical marijuana briefing: companies prepare for increased production as sector quickly expands: DirectView Holdings, Inc. (OTC: DIRV), PetroTech Oil and Gas, Inc. (OTC: PTOG), Dewmar International BMC Inc. (OTC: DEWM), Nuvilex, Inc. (OTC: NVLX) and Oculus Innovative Sciences Inc. (NASDAQ: OCLS)
Legalized Cannabis Sector Explodes as Companies Seek Opportunities in CO & WA
PR Newswire - Wed Feb 19, 12:13PM CST
Medical marijuana companies rapidly expand as restrictions lessen and demand increases: PetroTech Oil and Gas Inc. (OTC: PTOG), Webxu, Inc. (OTC: WBXU), Dewmar International BMC Inc. (OTC: DEWM), Nuvilex, Inc. (OTC: NVLX) and Chelsea Therapeutics Ltd. (NASDAQ: CHTP)
Nuvilex's Pancreatic Cancer Treatment Readies to Challenge Eli Lilly and Celgene in Late-Phase Clinical Trials
Marketwire - Wed Feb 19, 8:03AM CST
Nuvilex, Inc. (OTCQB: NVLX) is a small biotech firm in Silver Spring, Maryland, that hopes to soon be mentioned with much larger biotechnology and pharmaceutical companies like Eli Lilly and Celgene. If the company's pancreatic cancer treatment that combines the proprietary cellulose-based live-cell encapsulation technology known as Cell-in-a-Box(TM) with the anti-cancer drug ifosfamide can produce the same or better data in its upcoming late-phase clinical trials in advanced, inoperable pancreatic cancer than were seen with this same combination in two earlier independent Phase II trials, then not only will it be mentioned with those larger companies, Nuvilex's treatment will likely be the new "gold standard" for the disease.
Congressional Legislators Agree With Nuvilex's Dr. Mark Rabe on Reclassifying Marijuana
Marketwire - Fri Feb 14, 8:01AM CST
Nuvilex, Inc.'s (OTCQB: NVLX) Dr. Mark L. Rabe has something in common with 18 members of Congress. All of them want marijuana reclassified from its current listing as a dangerous drug with no medical value, and they want President Obama to use his authority to make that change by removing marijuana from the Schedule I category. Currently marijuana is viewed in the same category as drugs like heroin and LSD, and in a letter sent to the president this week, 18 legislators said this status "makes no sense."
Gathu Recovery Gives Thika United Clean Bill of Health Ahead of Tusker Test
by Francis Wadegu - All Africa Global Media - Fri Feb 14, 4:36AM CST
Thika United coach John Kamau is positive of registering good result on Sunday, when his Brookside-sponsored side take on 2012 champions Tusker in a Kenya Premier League season opener at City Stadium.
Government Committed to Provide Housing - Minister
by Augustine Osayande - All Africa Global Media - Thu Feb 13, 7:32AM CST
THE Minister of Labour and Productivity, Emeka Wogu, has reiterated federal government's commitment to provide affordable housing to Nigerian workers.
Nuvilex's Dr. Mark Rabe Talks Medical Marijuana, Legalization and Cell-in-a-Box
Marketwire - Wed Feb 12, 8:02AM CST
Nuvilex, Inc. (OTCQB: NVLX) is a biotechnology company that's focused on getting into late phase clinical trials for the treatment of advanced, inoperable pancreatic cancer, but it also expects to be a major player in the medical marijuana arena. And, to that end, last December, Nuvilex landed a leading figure in the medical marijuana field in Dr. Mark L. Rabe. Dr. Rabe was appointed as the Chairman of the Scientific Advisory Board of Medical Marijuana Sciences (MMS), the wholly-owned subsidiary Nuvilex formed to house its work in the Cannabis industry.
Medical Marijuana Could Bring Nuvilex and the National Football League Together
Marketwire - Wed Feb 05, 8:02AM CST
Nuvilex, Inc. (OTCQB: NVLX) entered the medical marijuana arena in 2013 as a biotech that would use its expertise to develop treatments for hard to treat cancers. The company said it will initially utilize cannabidiol, one of the compounds found in Cannabis, as the basis for developing treatments for some of the deadliest forms of cancer, namely pancreatic cancer and cancers of the brain, that have historically shown they're extremely difficult to treat.
Nuvilex to Use Proprietary Cell-in-a-Box Technology to Develop Marijuana-Based Cancer Treatments
GlobeNewswire - Mon Feb 03, 8:30AM CST
Nuvilex, Inc. (OTCQB:NVLX), an international biotechnology company providing cell and gene therapy solutions for the treatment of deadly diseases, announced today that its subsidiary, Medical Marijuana Sciences, Inc., plans to use the unique and proprietary cellulose-based live-cell encapsulation technology known as Cell-in-a-Box to develop treatments for serious and deadly forms of cancer. The revolutionary treatments will deliver cancer-fighting agents based on constituents of Cannabis (marijuana) that are known as cannabinoids.
Reading between the Lines of 4 Marijuana Penny Stocks: Nuvilex Inc. (OTCQB - NVLX), FusionPharm Inc. (OTCPINK: FSPM), Growlife Inc. (OTCBB: PHOT), Hemp Inc. (OTCPINK: HEMP)
ACCESSWIRE - Mon Feb 03, 7:11AM CST
As the frenzy being triggered by the astronomical potential of the legal-marijuana industry reaches a fever's pitch, so does the hype coming from marijuana penny stocks. In the interest of trying to encourage cooler heads among investors, here are four penny stocks where you should carefully read behind the lines of their super-positive news releases. High Stock Volume
Nuvilex (NVLX) Acquires 14.5% Equity Interest in Austrianova
GlobeNewswire - Thu Jan 30, 8:15AM CST
Nuvilex, Inc. (OTCQB:NVLX), an international biotechnology company providing cell and gene therapy solutions for the treatment of diseases, announced today that it has received its share issuance from SGAustria Pte. Ltd. (Austrianova), who owns Austrianova Singapore Pte. Ltd. (Austrianova Singapore), that equates to a 14.5% equity interest in Austrianova.
Nuvilex Appoints Dr. Garret L. Yount to Its Subsidiary's Scientific Advisory Board
GlobeNewswire - Fri Mar 07, 9:23AM CST
Nuvilex, Inc. (OTCQB:NVLX), an international biotechnology company providing cell and gene therapy solutions for the treatment of deadly diseases, announced today that its subsidiary, Medical Marijuana Sciences, Inc., has appointed Garret L. Yount, Ph.D. to its Scientific Advisory Board.
Nuvilex Partner Austrianova Establishes Regional Headquarters and Research and Development Facility at Thailand Science Park for Cell-in-a-Box(TM) Live-Cell Encapsulation
GlobeNewswire - Fri Mar 07, 2:59AM CST
Nuvilex, Inc. (OTCQB:NVLX), an international biotechnology company providing cell and gene therapy solutions for the treatment of diseases, announced today that its strategic partner, Austrianova, has signed a contract to establish regional Headquarters and a research and development facility at the Thailand Science Park (TSP) near Bangkok, Thailand. These facilities will be used for the encapsulation, using the Cell-in-a-Box technology, of live cancer prodrug-activating cells that are part of Nuvilex's pancreatic cancer treatment and that will be used in the Company's late-phase clinical trials involving this deadly disease.
Recent Events Effectively De-Risk Nuvilex, Inc.
PR Newswire - Thu Mar 06, 7:00AM CST
Goldman Small Cap Research, a stock market research firm focused on the small cap and micro cap sectors, recently published a new research update on Nuvilex Inc. (OTCQB: NVLX). In the update, senior analyst Rob Goldman outlines his latest thesis.
DirectView Enters Agreement with Colorado Marijuana Facility Developer; CannaBusiness Acquires NorCal Connection LLC
ACCESSWIRE - Wed Feb 26, 11:09AM CST
West Palm Beach, FL / February 26, 2014 / The Cannabis-Marijuana Sector is rapidly expanding as industry up and coming companies position themselves in this exploding sector. Four companies issuing news today are DirectView Holdings, Inc. (OTC: DIRV), The CannaBusiness Group, Inc (OTC: CBGI), Nuvilex, Inc. (OTC: NVLX) and PetroTech Oil and Gas, Inc. (OTC: PTOG). To be one of the first to get news as it occurs, visit http://www.marketnewsupdates.com/.
Nuvilex Comprehensive Analyst Report Answers Vital Questions for Shareholders, by BrokerBank Securities, Inc.
PR Newswire - Wed Feb 26, 6:00AM CST
Nuvilex, Inc. (OTCQB: NVLX) owns exclusive rights to a cancer treatment platform that has successfully completed Phase 2 clinical trials for inoperable pancreatic cancer. Nuvilex also owns rights to the same platform to treat diabetes, and the company also has a medical marijuana subsidiary slated to begin cancer research and development using cannabidiol. With each of the key target markets representing multi-billion-dollar opportunities, Nuvilex offers investors multiple opportunities for success and should trade at a valuation that reflects its current development progress to date.
10-K: OGE ENERGY CORP.
Edgar Online - Tue Feb 25, 7:22AM CST
Item 7. Management's Discussion and Analysis of Financial Condition and Results of Operations.
Chicago Investment Firm Assumes $27 Million Risk to Help Nuvilex Unseat Celgene and Eli Lilly
Marketwire - Mon Feb 24, 8:04AM CST
Lincoln Park Capital (LPC) purchased 8 million restricted shares of Nuvilex, Inc. (OTCQB: NVLX) in exchange for an initial $2 million out of what can be viewed as a $27 million "pot of money" to advance the company's late-phase pancreatic cancer clinical trials. Notice we said restricted shares, that's right, LPC has put a great deal of its money on the line with a number of built in protections for Nuvilex. But, is this investment really a risk? It appears the Chicago-based firm knows exactly what the future could hold for Nuvilex, and they're comfortable with paying a premium price to become a long-term investor right along with many others who believe in the small biotechnology firm.
Move Over Celgene Here Comes Nuvilex and $27 Million to Advance Its Pancreatic Cancer Clinical Trials
Marketwire - Fri Feb 21, 8:00AM CST
Nuvilex, Inc. (OTCQB: NVLX) just became relevant in the biotech industry. The company can now move forward with its clinical trials for the treatment of advanced inoperable pancreatic cancer after Nuvilex landed a $27 million funding deal that could change the sector for years to come. Funding is always the biggest hurdle for any small biotechnology or pharmaceutical firm, and its why larger firms with competing treatments can often sit back without worry of new competition.
Nuvilex Announces $27 Million Funding Commitment With Institutional Investor to Advance Late Phase Clinical Trials
GlobeNewswire - Thu Feb 20, 8:00AM CST
Nuvilex, Inc. (OTCQB:NVLX), an international biotechnology company providing cell and gene therapy solutions for the treatment of deadly diseases, announced today that it has entered into a stock purchase agreement with Lincoln Park Capital Fund, LLC (Lincoln Park), a Chicago-based institutional investor. Lincoln Park initially purchased 8 million shares of Nuvilex's common stock at $0.25 per share for $2 million and has committed to invest, at the sole option of Nuvilex, up to an additional $25 million of equity capital over the term of the purchase agreement. The proceeds from this investment will be used for Nuvilex's late-stage clinical trials in advanced inoperable pancreatic cancer, for research into the use of constituents of marijuana in the emerging medical marijuana arena and for general operating purposes.
Company To Provide Video Surveillance & Security Platform for Marijuana Facilities in Rapidly Evolving Cannabis Industry
PR Newswire - Thu Feb 20, 7:45AM CST
Medical marijuana briefing: companies prepare for increased production as sector quickly expands: DirectView Holdings, Inc. (OTC: DIRV), PetroTech Oil and Gas, Inc. (OTC: PTOG), Dewmar International BMC Inc. (OTC: DEWM), Nuvilex, Inc. (OTC: NVLX) and Oculus Innovative Sciences Inc. (NASDAQ: OCLS)
Legalized Cannabis Sector Explodes as Companies Seek Opportunities in CO & WA
PR Newswire - Wed Feb 19, 12:13PM CST
Medical marijuana companies rapidly expand as restrictions lessen and demand increases: PetroTech Oil and Gas Inc. (OTC: PTOG), Webxu, Inc. (OTC: WBXU), Dewmar International BMC Inc. (OTC: DEWM), Nuvilex, Inc. (OTC: NVLX) and Chelsea Therapeutics Ltd. (NASDAQ: CHTP)
Nuvilex's Pancreatic Cancer Treatment Readies to Challenge Eli Lilly and Celgene in Late-Phase Clinical Trials
Marketwire - Wed Feb 19, 8:03AM CST
Nuvilex, Inc. (OTCQB: NVLX) is a small biotech firm in Silver Spring, Maryland, that hopes to soon be mentioned with much larger biotechnology and pharmaceutical companies like Eli Lilly and Celgene. If the company's pancreatic cancer treatment that combines the proprietary cellulose-based live-cell encapsulation technology known as Cell-in-a-Box(TM) with the anti-cancer drug ifosfamide can produce the same or better data in its upcoming late-phase clinical trials in advanced, inoperable pancreatic cancer than were seen with this same combination in two earlier independent Phase II trials, then not only will it be mentioned with those larger companies, Nuvilex's treatment will likely be the new "gold standard" for the disease.
Congressional Legislators Agree With Nuvilex's Dr. Mark Rabe on Reclassifying Marijuana
Marketwire - Fri Feb 14, 8:01AM CST
Nuvilex, Inc.'s (OTCQB: NVLX) Dr. Mark L. Rabe has something in common with 18 members of Congress. All of them want marijuana reclassified from its current listing as a dangerous drug with no medical value, and they want President Obama to use his authority to make that change by removing marijuana from the Schedule I category. Currently marijuana is viewed in the same category as drugs like heroin and LSD, and in a letter sent to the president this week, 18 legislators said this status "makes no sense."
Gathu Recovery Gives Thika United Clean Bill of Health Ahead of Tusker Test
by Francis Wadegu - All Africa Global Media - Fri Feb 14, 4:36AM CST
Thika United coach John Kamau is positive of registering good result on Sunday, when his Brookside-sponsored side take on 2012 champions Tusker in a Kenya Premier League season opener at City Stadium.
Government Committed to Provide Housing - Minister
by Augustine Osayande - All Africa Global Media - Thu Feb 13, 7:32AM CST
THE Minister of Labour and Productivity, Emeka Wogu, has reiterated federal government's commitment to provide affordable housing to Nigerian workers.
Nuvilex's Dr. Mark Rabe Talks Medical Marijuana, Legalization and Cell-in-a-Box
Marketwire - Wed Feb 12, 8:02AM CST
Nuvilex, Inc. (OTCQB: NVLX) is a biotechnology company that's focused on getting into late phase clinical trials for the treatment of advanced, inoperable pancreatic cancer, but it also expects to be a major player in the medical marijuana arena. And, to that end, last December, Nuvilex landed a leading figure in the medical marijuana field in Dr. Mark L. Rabe. Dr. Rabe was appointed as the Chairman of the Scientific Advisory Board of Medical Marijuana Sciences (MMS), the wholly-owned subsidiary Nuvilex formed to house its work in the Cannabis industry.
Medical Marijuana Could Bring Nuvilex and the National Football League Together
Marketwire - Wed Feb 05, 8:02AM CST
Nuvilex, Inc. (OTCQB: NVLX) entered the medical marijuana arena in 2013 as a biotech that would use its expertise to develop treatments for hard to treat cancers. The company said it will initially utilize cannabidiol, one of the compounds found in Cannabis, as the basis for developing treatments for some of the deadliest forms of cancer, namely pancreatic cancer and cancers of the brain, that have historically shown they're extremely difficult to treat.
Nuvilex to Use Proprietary Cell-in-a-Box Technology to Develop Marijuana-Based Cancer Treatments
GlobeNewswire - Mon Feb 03, 8:30AM CST
Nuvilex, Inc. (OTCQB:NVLX), an international biotechnology company providing cell and gene therapy solutions for the treatment of deadly diseases, announced today that its subsidiary, Medical Marijuana Sciences, Inc., plans to use the unique and proprietary cellulose-based live-cell encapsulation technology known as Cell-in-a-Box to develop treatments for serious and deadly forms of cancer. The revolutionary treatments will deliver cancer-fighting agents based on constituents of Cannabis (marijuana) that are known as cannabinoids.
Reading between the Lines of 4 Marijuana Penny Stocks: Nuvilex Inc. (OTCQB - NVLX), FusionPharm Inc. (OTCPINK: FSPM), Growlife Inc. (OTCBB: PHOT), Hemp Inc. (OTCPINK: HEMP)
ACCESSWIRE - Mon Feb 03, 7:11AM CST
As the frenzy being triggered by the astronomical potential of the legal-marijuana industry reaches a fever's pitch, so does the hype coming from marijuana penny stocks. In the interest of trying to encourage cooler heads among investors, here are four penny stocks where you should carefully read behind the lines of their super-positive news releases. High Stock Volume
Nuvilex (NVLX) Acquires 14.5% Equity Interest in Austrianova
GlobeNewswire - Thu Jan 30, 8:15AM CST
Nuvilex, Inc. (OTCQB:NVLX), an international biotechnology company providing cell and gene therapy solutions for the treatment of diseases, announced today that it has received its share issuance from SGAustria Pte. Ltd. (Austrianova), who owns Austrianova Singapore Pte. Ltd. (Austrianova Singapore), that equates to a 14.5% equity interest in Austrianova.
(0)
(0)PharmaCyte Biotech Inc. (PMCB) Stock Research Links
Scroll down for more posts ▼